Background:
Pravastatin (Pra) exerts protective effects on preeclampsia.
In various mouse models of preeclampsia studied in the past decade,
pravastatin, a hydrophilic statin, has had beneficial effects.
In a study of men with very high LDL ("bad") cholesterol levels, but no other heart disease risk factors, the use of
pravastatin was found to reduce the risk of coronary heart disease by about 28 percent.
Researchers from Imperial College London and the University of Glasgow found impressive results among those on statins, who were given the widelyprescribed type
pravastatin.
A total of 1,467 were randomly assigned to receive
pravastatin and 1,400 to usual care (no statin therapy), and they were followed for 6 years.
The other two statins studied,
pravastatin and rosuvastatin, do not cross the blood-brain barrier.
In addition, 10,355 study participants with elevated cholesterol levels were randomized to either the high cholesterol drug
pravastatin or standard care.
The aim of this study was to assess the effects of
Pravastatin, a HMG-CoA reductase inhibitor, over a MM cell line, with a focus over cell cycle, inflammatory and growth factors response, cholesterol production and pleiotropic effects.
Treatment with simvastatin 20 to 40 mg, atorvastatin 10 mg, or
pravastatin 40 mg was defined as moderate.
The primary prevention study randomized 6,595 middle-aged Scotsmen with an average baseline LDL cholesterol of 190 mg/dL to 4 years of
pravastatin at 40 mg/day or placebo.
Researchers reviewed data from 135 studies to evaluate the safety of seven statin drugs: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Mevacor), pitavastatin (Levalo),
pravastatin (Pravachol), rosuvastatin (Crestor) and simvastatin (Zocor).
Rats given daily doses of
pravastatin - sold as Pravachol - had to recognise a previously seen object and find a food reward.
